Vimekofusp clinical trials
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses vimekofusp is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Applied Molecular Transport (4)
Studies
Open first, then newest update. How each study uses vimekofusp is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD)Status unknownPhase 2Applied Molecular TransportNCT04583358Written as AMT-101 (oral)
- Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET)CompletedPhase 2Applied Molecular TransportNCT05372939Written as AMT-101 (oral)
- Study of the Safety and Efficacy of AMT-101 in Subjects With PouchitisCompletedPhase 2Applied Molecular TransportNCT04741087Written as AMT-101 (oral)-Dose A
- SAD/MAD Study in Healthy Subjects and Adults With UC to Evaluate Safety, Tolerability, PK, PD of AMT-101CompletedPhase 1Applied Molecular TransportNCT04224857Written as AMT-101
Codes
What other systems call vimekofusp · ClinicalTrials.gg INT017724
- UNII (FDA) QX77JY19LDVIMEKOFUSPOne source FDA
- NCI Thesaurus C203052VimekofuspOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | QX77JY19LD | VIMEKOFUSP | One source FDA |
| NCI Thesaurus | C203052 | Vimekofusp | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.